About BioScience GmbH TECHNOLOGY & PATENTS Investing our efforts in developing cutting-edge technologies is our top priority to offer
products of the highest quality and safety profile.

Advanced Thixotropic
Technology (ATT)

Allows the synthesis of a special type of cross-linked hyaluronic acid gel

Advanced Thixotropic Technology (ATT) defines how molecules of hyaluronic acid gel behave during and after injection. It enables the gel to become less viscous under injection pressure and return to its original viscosity when pressure is released. This results in a long-lasting and stable effect of all our dermal fillers while also allowing injection with reduced force and thinner needles.

ATT
ATT2

Smart Cross-Linking
Technology (SCLT)

Surpasses standard cross-linking process to create a cohesive, polydensified matrix

As a result of Smart Cross-Linking Technology, our products provide significant improvements, especially for patients with extremely deep folds, ensuring outstanding efficacy and tolerability, as well as a natural look and feel.

Research

Selection of the best methods to produce stable, highly pure, and injection-optimized products is at the heart of what we do. Since our inception, research and development activities have been a core focus in our growth. Over the past two decades, our state-of-the-art facilities in Dummer, Germany, have patented unique technologies and engineered products of the highest standards. We constantly work on developing future products and key materials to further share our expertise and solutions with the industry.

Clinical Trials

Clinical testing is an essential aspect of our product development process. Almost 30 percent of our annual turnover is solely dedicated to R&D in the field of medical devices and aesthetics. We conduct clinical trials and evaluations regularly to test and re-confirm that our medical devices are some of the safest ones in the market.